|European Case Law Identifier:||ECLI:EP:BA:2021:T148918.20210322|
|Date of decision:||22 March 2021|
|Case number:||T 1489/18|
|IPC class:||C07K 16/28
|Language of proceedings:||EN|
|Download and more information:||
|Title of application:||Monoclonal antibodies against NKG2A|
|Applicant name:||Innate Pharma
Universita di Genova
|Opponent name:||Merck Sharp & Dohme Corp.|
|Relevant legal provisions:||
|Keywords:||Basis of decision - text or agreement to text withdrawn by patent proprietor
Basis of decision - patent revoked
Summary of Facts and Submissions
I. Appeals were lodged by the patent proprietors (appellants I) and the opponent (appellant II) against the opposition division's interlocutory decision according to which European patent No. 2 476 705 (the patent) as amended in the form of auxiliary request 2, and the invention to which it relates, were found to meet the requirements of the EPC.
II. With their statement of grounds of appeal appellants I requested that the decision under appeal be set aside and the patent be maintained on the basis of the claims as granted (main request), or alternatively on the basis of one of auxiliary requests 1 to 6. Oral proceedings were requested on an auxiliary basis.
III. In their statement of grounds of appeal appellant II requested that the decision under appeal be set aside and that the patent be revoked in its entirety for all designated states. Oral proceedings were requested on an auxiliary basis.
IV. Both parties replied to each other's statement of grounds of appeal.
V. The board summoned oral proceedings and issued a communication pursuant to Article 15(1) RPBA setting out its preliminary opinion.
VI. Upon request of appellants I the oral proceedings were rescheduled to take place on 22 and 23 March 2021. In a further communication the board informed the parties that the oral proceedings would be held by videoconference.
VII. With letter of 25 February 2021, appellant II informed the board that they would not attend the scheduled oral proceedings.
VIII. With letter of 16 March 2021, appellants I stated that at the oral proceedings they intended to defend the patentability of the main request and auxiliary request 1. They also filed a new auxiliary request 7.
IX. Oral proceedings before the board took place on 22 March 2021 in the absence of appellant II. At the end of the oral proceedings appellants I declared that they did no longer approve of the text of the patent in suit and of all claim requests on file. The also stated that no amended text would be submitted and requested that the patent be revoked.
X. At the end of the oral proceedings, the Chair announced the board's decision.
Reasons for the Decision
1. The appeals comply with Articles 106 to 108 and Rule 99 EPC and are therefore admissible.
2. Pursuant to Article 113(2) EPC the European Patent Office shall examine and decide upon the European patent only in the text submitted to it, or agreed, by the proprietor of the patent.
3. Such an agreement cannot be deemed to exist if the patent proprietors - as in the present case - expressly state that they no longer approve the text of the patent as granted and withdraw all pending claim requests (see section IX. above).
4. There is therefore no text of the patent on the basis of which the board can consider the appeals and compliance with the requirements of the EPC.
It is established case law that in these circumstances, the proceedings are to be terminated by a decision ordering revocation of the patent, without substantive examination as to patentability (see decision T 73/84, OJ EPO 1985, 241 and further decisions cited in Case Law of the Boards of Appeal of the European Patent Office, 9th Edition 2019, IV.D.2). The board has no reason in the present case to deviate from this consistent approach of the Boards of Appeal.
5. There are no remaining issues that need to be dealt with by the board in the present appeal case.
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The patent is revoked.